Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESO-TX102
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Cell Therapies, Gene Therapies
01
Overview
**ESO-TX102** is an early-stage, in vivo immune-cell-engineering candidate for **solid tumors** originated by EsoBiotec. It is described as a first-in-class combination candidate designed to simultaneously engineer T cells and monocytes in vivo, with the aim of remodeling the tumor microenvironment and improving antitumor immune activity. The program is based on EsoBiotec's ENaBL targeted lentiviral-vector platform; EsoBiotec became a wholly owned AstraZeneca subsidiary in May 2025. ([chromatinbio.com](https://www.chromatinbio.com/chromatin-biosciences-synthetic-promoter-supports-esobiotecs-eso-t01-car-t-therapy-as-it-enters-the-clinic))
Beyond the preview
Go deeper on ESO-TX102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ESO-TX102.